SSY GROUP (02005.HK): Calcium Chloride API Approved for Registration by NMPA

NewTimeSpace: SSY Group Limited (02005.HK) announced that its calcium chloride has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Calcium chloride is mainly indicated for the treatment of calcium deficiency, tetany and other conditions.
NewTimeSpace: SSY Group Limited  (02005.HK) issued a voluntary announcement on March 19, stating that its calcium chloride has been approved by the NMPA for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.
As an additive for intravenous injection solutions, calcium chloride is mainly used for the treatment of calcium deficiency, tetany, vitamin D deficiency and allergic diseases.
It is also applied to the rescue of magnesium poisoning, fluorine poisoning, and cardiac dysfunctions caused by hyperkalemia, hypocalcemia or calcium channel blockade.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.